KR20250005182A - 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민 - Google Patents

인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민 Download PDF

Info

Publication number
KR20250005182A
KR20250005182A KR1020247035759A KR20247035759A KR20250005182A KR 20250005182 A KR20250005182 A KR 20250005182A KR 1020247035759 A KR1020247035759 A KR 1020247035759A KR 20247035759 A KR20247035759 A KR 20247035759A KR 20250005182 A KR20250005182 A KR 20250005182A
Authority
KR
South Korea
Prior art keywords
dmt
meo
pharmaceutically acceptable
acceptable salt
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247035759A
Other languages
English (en)
Korean (ko)
Inventor
타이스 테르바이
코너 버크
나오이즈 가프니
Original Assignee
지에이치 리서치 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지에이치 리서치 아일랜드 리미티드 filed Critical 지에이치 리서치 아일랜드 리미티드
Publication of KR20250005182A publication Critical patent/KR20250005182A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
KR1020247035759A 2022-03-27 2023-03-27 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민 Pending KR20250005182A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP22000085.5 2022-03-27
EP22000085 2022-03-27
EP22000084.8 2022-03-27
EP22000084 2022-03-27
EP23153996 2023-01-30
EP23154014 2023-01-30
EP23154014.7 2023-01-30
EP23153996.6 2023-01-30
PCT/EP2023/057871 WO2023186824A1 (en) 2022-03-27 2023-03-27 5-methoxy-n,n-dimethyltryptamine for the treatment of cognitive dysfunction

Publications (1)

Publication Number Publication Date
KR20250005182A true KR20250005182A (ko) 2025-01-09

Family

ID=86007029

Family Applications (7)

Application Number Title Priority Date Filing Date
KR1020247035759A Pending KR20250005182A (ko) 2022-03-27 2023-03-27 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민
KR1020247035654A Pending KR20240167878A (ko) 2022-03-27 2023-03-27 정신운동지연의 치료를 위한 5-메톡시-n,n-디메틸트립타민
KR1020247035763A Pending KR20250005184A (ko) 2022-03-27 2023-03-27 사회적/감정적 위축 또는 분리의 치료를 위한 5-메톡시-n,n-다이메틸트립타민
KR1020247035657A Pending KR20250005173A (ko) 2022-03-27 2023-03-27 산후 우울증의 치료
KR1020247035707A Pending KR20250005175A (ko) 2022-03-27 2023-03-27 양극성 장애의 치료를 위한 5-meo-dtm
KR1020247035719A Pending KR20250005177A (ko) 2022-03-27 2023-03-27 불안 치료를 위한 5-메톡시-n,n-다이메틸트립타민
KR1020247035720A Pending KR20250005178A (ko) 2022-03-27 2023-03-27 수면 장애의 치료에 사용하기 위한 5-meo-dmt

Family Applications After (6)

Application Number Title Priority Date Filing Date
KR1020247035654A Pending KR20240167878A (ko) 2022-03-27 2023-03-27 정신운동지연의 치료를 위한 5-메톡시-n,n-디메틸트립타민
KR1020247035763A Pending KR20250005184A (ko) 2022-03-27 2023-03-27 사회적/감정적 위축 또는 분리의 치료를 위한 5-메톡시-n,n-다이메틸트립타민
KR1020247035657A Pending KR20250005173A (ko) 2022-03-27 2023-03-27 산후 우울증의 치료
KR1020247035707A Pending KR20250005175A (ko) 2022-03-27 2023-03-27 양극성 장애의 치료를 위한 5-meo-dtm
KR1020247035719A Pending KR20250005177A (ko) 2022-03-27 2023-03-27 불안 치료를 위한 5-메톡시-n,n-다이메틸트립타민
KR1020247035720A Pending KR20250005178A (ko) 2022-03-27 2023-03-27 수면 장애의 치료에 사용하기 위한 5-meo-dmt

Country Status (9)

Country Link
US (10) US20250235427A1 (cg-RX-API-DMAC7.html)
EP (8) EP4499085A1 (cg-RX-API-DMAC7.html)
JP (7) JP2025510294A (cg-RX-API-DMAC7.html)
KR (7) KR20250005182A (cg-RX-API-DMAC7.html)
CN (5) CN119546298A (cg-RX-API-DMAC7.html)
AU (7) AU2023244447A1 (cg-RX-API-DMAC7.html)
CA (7) CA3255652A1 (cg-RX-API-DMAC7.html)
IL (7) IL315895A (cg-RX-API-DMAC7.html)
WO (9) WO2023186832A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
EP4277894A1 (en) 2021-01-15 2023-11-22 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202306256D0 (en) * 2023-04-27 2023-06-14 Beckley Psytech Ltd 5-Methoxy-N,N-Dimethyltryptamine Formulations
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
WO2026078143A1 (en) 2024-10-09 2026-04-16 GH Research Ireland Limited Combinations of 5-meo-dmt with antidepressants for treating depression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200147038A1 (en) * 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
DK3927338T3 (da) * 2019-02-22 2025-01-06 Gh Res Ireland Limited Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
KR20220008824A (ko) * 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
LT4084791T (lt) * 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
US20230157981A1 (en) * 2020-04-20 2023-05-25 Lobe Sciences Ltd. Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder
BR112022025306A2 (pt) * 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
US11406619B2 (en) * 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
WO2022189662A1 (en) * 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
CA3216889A1 (en) * 2021-04-26 2022-11-03 Glenn Short Novel n,n-dimethyltryptamine compositions and methods
WO2023028086A1 (en) * 2021-08-23 2023-03-02 Gilgamesh Pharmaceuticals, Inc. Combinations of peripheral 5-ht2a receptor antagonists and central 5-ht2a receptor agonists
AU2022413759A1 (en) * 2021-12-13 2024-06-27 Beckley Psytech Limited Benzoate salt of 5-methoxy-n,n-dimethyltryptamine

Also Published As

Publication number Publication date
AU2023244447A1 (en) 2024-11-07
US20250213528A1 (en) 2025-07-03
KR20250005177A (ko) 2025-01-09
AU2023244449A1 (en) 2024-11-07
US20250213533A1 (en) 2025-07-03
KR20250005178A (ko) 2025-01-09
EP4499072A1 (en) 2025-02-05
JP2025511084A (ja) 2025-04-15
JP2025510914A (ja) 2025-04-15
JP2025510296A (ja) 2025-04-14
US20250170099A1 (en) 2025-05-29
WO2023186821A1 (en) 2023-10-05
KR20250005184A (ko) 2025-01-09
US20240115549A1 (en) 2024-04-11
CA3255329A1 (en) 2023-10-05
JP2025510294A (ja) 2025-04-14
AU2023244453A1 (en) 2024-11-07
US20250213529A1 (en) 2025-07-03
EP4499078A1 (en) 2025-02-05
IL315905A (en) 2024-11-01
KR20250005173A (ko) 2025-01-09
KR20240167878A (ko) 2024-11-28
IL315904A (en) 2024-11-01
EP4499077A1 (en) 2025-02-05
EP4499084A1 (en) 2025-02-05
US20250213531A1 (en) 2025-07-03
US20250213534A1 (en) 2025-07-03
AU2023242439A1 (en) 2024-11-07
WO2023186824A1 (en) 2023-10-05
WO2023186837A1 (en) 2023-10-05
CA3255654A1 (en) 2023-10-05
CA3255338A1 (en) 2023-10-05
CN119546298A (zh) 2025-02-28
IL315901A (en) 2024-11-01
CN119278036A (zh) 2025-01-07
EP4499089A1 (en) 2025-02-05
AU2023246773A1 (en) 2024-11-07
CN119156212A (zh) 2024-12-17
EP4499085A1 (en) 2025-02-05
CA3255640A1 (en) 2023-10-05
US20250213530A1 (en) 2025-07-03
JP2025510295A (ja) 2025-04-14
EP4499081A1 (en) 2025-02-05
IL315895A (en) 2024-11-01
JP2025512866A (ja) 2025-04-22
US20250235427A1 (en) 2025-07-24
CA3255652A1 (en) 2023-10-05
EP4499074A1 (en) 2025-02-05
CN119255798A (zh) 2025-01-03
AU2023246681A1 (en) 2024-11-07
CN119255799A (zh) 2025-01-03
WO2023186798A1 (en) 2023-10-05
US20240115550A1 (en) 2024-04-11
IL315903A (en) 2024-11-01
WO2023186827A1 (en) 2023-10-05
WO2023186828A1 (en) 2023-10-05
WO2023186808A1 (en) 2023-10-05
AU2023246548A1 (en) 2024-11-07
CA3255709A1 (en) 2023-10-05
WO2023186832A1 (en) 2023-10-05
KR20250005175A (ko) 2025-01-09
IL315900A (en) 2024-11-01
IL315892A (en) 2024-11-01
JP2025510913A (ja) 2025-04-15
WO2023186831A1 (en) 2023-10-05
CA3255511A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
EP4499078A1 (en) 5-methoxy-n,n-dimethyltryptamine for the treatment of cognitive dysfunction
KR20250005181A (ko) 인지 기능장애 치료
KR20250138805A (ko) 정신 장애의 치료
KR20250139377A (ko) 수유부의 정신 장애 치료에 사용하기 위한 5-메톡시-n,n-다이메틸트립타민

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000